Effectiveness of climatotherapy at the Dead Sea for psoriasis vulgaris: A community‐oriented study introducing the ‘Beer Sheva Psoriasis Severity Score’

References

• Abel E. A., Barnes S., Le Vine M. J., Seidman D. R., Wallk S. Psoriasis treatment at the Dead Sea: Second International Study Tour. J Am Acad Dermatol 1988; 19((2 Pt 1))362–4
   Google Scholar
• Abels D. J., Kattan‐Byron J. Psoriasis treatment at the Dead Sea: a natural selective ultraviolet phototherapy. J Am Acad Dermatol 1985; 12: 639–43
   PubMed Web of Science ®Google Scholar
• Abels D. J., Harari M. Psoriasis remission time at the Dead Sea. J Am Acad Dermatol 2000; 43((2 Pt 1))325–6
   Google Scholar
• Azizi E., Kushelevsky A. P., Avrach W., Schewach‐Millet M. Climate therapy for psoriasis at the Dead Sea, Israel. Isr J Med Sci 1982; 18: 267–70
   PubMedGoogle Scholar
• David M., Efron D., Hodak E., Even‐Paz Z. Treatment of psoriasis at the Dead Sea: why, how and when?. Isr Med Assoc J 2000; 2: 232–4
   Google Scholar
• Duvic M., Goldberg G., Prawer S. E., Brenn P., Hefter H. S. Climatotherapy of psoriasis at the Dead Sea. J Am Acad Dermatol 1986; 15: 1298–301
   Google Scholar
• Duvic M. Possible mechanisms of effectiveness of Dead Sea balneotherapy. J Am Acad Dermatol 1986; 15((5 Pt 1))1061
   Google Scholar
• Even‐Paz Z. Dermatology at the Dead Sea spas. Isr J Med Sci 1996; 32((Suppl))S11–S15
   Google Scholar
• Even‐Paz Z., Efron D. Determination of solar ultraviolet dose in the Dead Sea treatment of psoriasis. Isr Med Assoc J 2003; 5: 87–8
   Google Scholar
• Gambichler T., Altmeyer P., Hoffmann K. Cost‐effectiveness of Dead‐Sea climatotherapy and balneophototherapy of psoriasis. Int J Dermatol 2001; 40: 158–9
   Google Scholar
• Halevy S., Sukenik S. Different modalities of spa therapy for skin diseases at the Dead Sea area. Arch Dermatol 1998; 134: 1416–20
   PubMedGoogle Scholar
• Halevy S., Giryes H., Friger M., Grossman N., Karpas Z., Sarov B., et al. The role of trace elements in psoriatic patients undergoing balneotherapy with Dead Sea bath salt. Isr Med Assoc J 2001; 3: 828–32
   PubMed Web of Science ®Google Scholar
• Harari M., Shani J. Demographic evaluation of successful antipsoriatic climatotherapy at the Dead Sea (Israel) DMZ Clinic. Int J Dermatol 1997; 36: 304–8
   Google Scholar
• Harari M., Shani J., Hristakieva E., Stanimirovic A., Seidl W., Burdo A. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead‐Sea. Int J Dermatol 2000; 39: 913–18
   PubMed Web of Science ®Google Scholar
• Hodak E., Gottlieb A. B., Segal T., Politi Y., Maron L., Sulkes J., et al. Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation. J Am Acad Dermatol 2003; 49: 451–7
   PubMed Web of Science ®Google Scholar
• Hodak E., Gottlieb A. B., Segal T., Maron L., Lotem M., Feinmesser M., et al. An open trial of climatotherapy at the Dead Sea for patch‐stage mycosis fungoides. J Am Acad Dermatol 2004; 51: 33–8
   Google Scholar
• Kudish A. I., Abels D., Harari M. Ultraviolet radiation properties as applied to photoclimatherapy at the Dead Sea. Int J Dermatol 2003; 42: 359–65
   PubMed Web of Science ®Google Scholar
• Kushelevsky A. P., Harari M., Hristakieva E., Shani J. Climatotherapy of psoriasis and hypertension in elderly patients at the Dead‐Sea. Pharmacol Res 1996; 34: 87–91
   Google Scholar
• Kushelevsky A. P., Harari M., Kudish A. I., Hristakieva E., Ingber A., Shani J. Safety of solar phototherapy at the Dead Sea. J Am Acad Dermatol 1998; 38: 447–52
   PubMed Web of Science ®Google Scholar
• Matz H., Orion E., Wolf R. Balneotherapy in dermatology. Dermatol Ther 2003; 16: 132–40
   PubMedGoogle Scholar
• Montgomery B. J. Bathing for psoriasis in the Dead Sea. JAMA 1979; 241: 227–31
   Google Scholar
• Paltiel O., Adler B., Herschko K., Tsukrov B., David M. Are patients with psoriasis susceptible to the classic risk factors for actinic keratoses?. Arch Dermatol 2004; 140: 805–10
   Google Scholar
• Sapeika N. Treatment of psoriasis at the Dead Sea. S Afr Med J 1976; 50: 2021
   Google Scholar
• Schamberg I. L. Treatment of psoriasis at the Dead Sea. Int J Dermatol 1978; 17: 524–5
   Google Scholar
• Schiffner R., Schiffner‐Rohe J., Gerstenhauer M., Hofstadter F., Landthaler M., Stolz W. Differences in efficacy between intention‐to‐treat and per‐protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. Br J Dermatol 2001; 144: 1154–60
   Google Scholar
• Schiffner R., Schiffner‐Rohe J., Gerstenhauer M., Hofstadter F., Landthaler M., Stolz W. Willingness to pay and time trade‐off: sensitive to changes of quality of life in psoriasis patients?. Br J Dermatol 2003; 148: 1153–60
   PubMed Web of Science ®Google Scholar
• Shani J., Harari M., Hristakieva E., Seidl V., Bar‐Giyora J. Dead‐Sea climatotherapy versus other modalities of treatment for psoriasis: comparative cost‐effectiveness. Int J Dermatol 1999; 38: 252–62
   Google Scholar
• Weinrauch L. The cost of psoriasis treatment at the Dead Sea. Int J Dermatol 1996; 35: 150–1
   Google Scholar
• Wolf R., Orion E., Matz H. Climatotherapy: there is life in the Dead Sea. Isr Med Assoc J 2003; 5: 124–5
   Google Scholar
• Schallreuter K. U., Moore J., Behrens‐Williams S., Panske A., Harari M. Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC‐KUS). Int J Dermatol 2002; 41: 482–7
   PubMed Web of Science ®Google Scholar
• Fredriksson T., Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157: 238–44
   PubMedGoogle Scholar
• Carlin C. S., Feldman S. R., Krueger J. G., Menter A., Krueger G. G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859–66
   PubMed Web of Science ®Google Scholar
• Krueger G. G., Papp K. A., Stough D. B., Loven K. H., Gulliver W. P., Ellis C. N. A randomized, double‐blind, placebo‐controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821–33
   PubMed Web of Science ®Google Scholar
• Lebwohl M., Christophers E., Langley R., Ortonne J. P., Roberts J., Griffiths C. E. An international, randomized, double‐blind, placebo‐controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719–27
   PubMed Web of Science ®Google Scholar